PMC:7534795 / 50943-51970 JSONTXT

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T82","span":{"begin":256,"end":261},"obj":"Body_part"}],"attributes":[{"id":"A82","pred":"uberon_id","subj":"T82","obj":"http://purl.obolibrary.org/obo/UBERON_0002542"}],"text":"Currently, there are multiple in vitro experiments and preclinical studies being performed around the world to test novel COVID-19 therapies, which are quickly moving into clinical trials. Importantly, the early efficacy results have been limited to small-scale clinical studies in which the safety profiles have not been well-identified. The safety profiles will be critical for COVID-19 patients with underlying comorbidities such as cardiovascular dysfunction. Therefore, as there is a need for rapid clinical translation and a wide use of novel therapies for COVID-19, continued attention to safety profiles is important. The rapid spread of COVID-19 globally continues to impact susceptible populations, like elderly patients and individuals with underlying comorbidities. While underlying cardiovascular issues are impacted by COVID-19 infection, many existing and novel therapeutic strategies have direct adverse cardiovascular effects, highlighting the importance for consideration in new drug research and development."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T384","span":{"begin":122,"end":130},"obj":"Disease"},{"id":"T385","span":{"begin":380,"end":388},"obj":"Disease"},{"id":"T386","span":{"begin":563,"end":571},"obj":"Disease"},{"id":"T387","span":{"begin":646,"end":654},"obj":"Disease"},{"id":"T388","span":{"begin":833,"end":841},"obj":"Disease"},{"id":"T389","span":{"begin":842,"end":851},"obj":"Disease"}],"attributes":[{"id":"A384","pred":"mondo_id","subj":"T384","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A385","pred":"mondo_id","subj":"T385","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A386","pred":"mondo_id","subj":"T386","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A387","pred":"mondo_id","subj":"T387","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A388","pred":"mondo_id","subj":"T388","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A389","pred":"mondo_id","subj":"T389","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"}],"text":"Currently, there are multiple in vitro experiments and preclinical studies being performed around the world to test novel COVID-19 therapies, which are quickly moving into clinical trials. Importantly, the early efficacy results have been limited to small-scale clinical studies in which the safety profiles have not been well-identified. The safety profiles will be critical for COVID-19 patients with underlying comorbidities such as cardiovascular dysfunction. Therefore, as there is a need for rapid clinical translation and a wide use of novel therapies for COVID-19, continued attention to safety profiles is important. The rapid spread of COVID-19 globally continues to impact susceptible populations, like elderly patients and individuals with underlying comorbidities. While underlying cardiovascular issues are impacted by COVID-19 infection, many existing and novel therapeutic strategies have direct adverse cardiovascular effects, highlighting the importance for consideration in new drug research and development."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T310","span":{"begin":111,"end":115},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"},{"id":"T311","span":{"begin":487,"end":488},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T312","span":{"begin":529,"end":530},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"Currently, there are multiple in vitro experiments and preclinical studies being performed around the world to test novel COVID-19 therapies, which are quickly moving into clinical trials. Importantly, the early efficacy results have been limited to small-scale clinical studies in which the safety profiles have not been well-identified. The safety profiles will be critical for COVID-19 patients with underlying comorbidities such as cardiovascular dysfunction. Therefore, as there is a need for rapid clinical translation and a wide use of novel therapies for COVID-19, continued attention to safety profiles is important. The rapid spread of COVID-19 globally continues to impact susceptible populations, like elderly patients and individuals with underlying comorbidities. While underlying cardiovascular issues are impacted by COVID-19 infection, many existing and novel therapeutic strategies have direct adverse cardiovascular effects, highlighting the importance for consideration in new drug research and development."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T47","span":{"begin":997,"end":1001},"obj":"Chemical"}],"attributes":[{"id":"A13013","pred":"chebi_id","subj":"T47","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"}],"text":"Currently, there are multiple in vitro experiments and preclinical studies being performed around the world to test novel COVID-19 therapies, which are quickly moving into clinical trials. Importantly, the early efficacy results have been limited to small-scale clinical studies in which the safety profiles have not been well-identified. The safety profiles will be critical for COVID-19 patients with underlying comorbidities such as cardiovascular dysfunction. Therefore, as there is a need for rapid clinical translation and a wide use of novel therapies for COVID-19, continued attention to safety profiles is important. The rapid spread of COVID-19 globally continues to impact susceptible populations, like elderly patients and individuals with underlying comorbidities. While underlying cardiovascular issues are impacted by COVID-19 infection, many existing and novel therapeutic strategies have direct adverse cardiovascular effects, highlighting the importance for consideration in new drug research and development."}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T95","span":{"begin":513,"end":524},"obj":"http://purl.obolibrary.org/obo/GO_0006412"}],"text":"Currently, there are multiple in vitro experiments and preclinical studies being performed around the world to test novel COVID-19 therapies, which are quickly moving into clinical trials. Importantly, the early efficacy results have been limited to small-scale clinical studies in which the safety profiles have not been well-identified. The safety profiles will be critical for COVID-19 patients with underlying comorbidities such as cardiovascular dysfunction. Therefore, as there is a need for rapid clinical translation and a wide use of novel therapies for COVID-19, continued attention to safety profiles is important. The rapid spread of COVID-19 globally continues to impact susceptible populations, like elderly patients and individuals with underlying comorbidities. While underlying cardiovascular issues are impacted by COVID-19 infection, many existing and novel therapeutic strategies have direct adverse cardiovascular effects, highlighting the importance for consideration in new drug research and development."}

{"project":"LitCovid-sentences","denotations":[{"id":"T419","span":{"begin":0,"end":188},"obj":"Sentence"},{"id":"T420","span":{"begin":189,"end":338},"obj":"Sentence"},{"id":"T421","span":{"begin":339,"end":463},"obj":"Sentence"},{"id":"T422","span":{"begin":464,"end":625},"obj":"Sentence"},{"id":"T423","span":{"begin":626,"end":777},"obj":"Sentence"},{"id":"T424","span":{"begin":778,"end":1027},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Currently, there are multiple in vitro experiments and preclinical studies being performed around the world to test novel COVID-19 therapies, which are quickly moving into clinical trials. Importantly, the early efficacy results have been limited to small-scale clinical studies in which the safety profiles have not been well-identified. The safety profiles will be critical for COVID-19 patients with underlying comorbidities such as cardiovascular dysfunction. Therefore, as there is a need for rapid clinical translation and a wide use of novel therapies for COVID-19, continued attention to safety profiles is important. The rapid spread of COVID-19 globally continues to impact susceptible populations, like elderly patients and individuals with underlying comorbidities. While underlying cardiovascular issues are impacted by COVID-19 infection, many existing and novel therapeutic strategies have direct adverse cardiovascular effects, highlighting the importance for consideration in new drug research and development."}

{"project":"LitCovid-PubTator","denotations":[{"id":"1527","span":{"begin":389,"end":397},"obj":"Species"},{"id":"1528","span":{"begin":722,"end":730},"obj":"Species"},{"id":"1529","span":{"begin":122,"end":130},"obj":"Disease"},{"id":"1530","span":{"begin":380,"end":388},"obj":"Disease"},{"id":"1531","span":{"begin":436,"end":462},"obj":"Disease"},{"id":"1532","span":{"begin":563,"end":571},"obj":"Disease"},{"id":"1533","span":{"begin":646,"end":654},"obj":"Disease"},{"id":"1534","span":{"begin":833,"end":841},"obj":"Disease"},{"id":"1535","span":{"begin":842,"end":851},"obj":"Disease"}],"attributes":[{"id":"A1527","pred":"tao:has_database_id","subj":"1527","obj":"Tax:9606"},{"id":"A1528","pred":"tao:has_database_id","subj":"1528","obj":"Tax:9606"},{"id":"A1529","pred":"tao:has_database_id","subj":"1529","obj":"MESH:C000657245"},{"id":"A1530","pred":"tao:has_database_id","subj":"1530","obj":"MESH:C000657245"},{"id":"A1531","pred":"tao:has_database_id","subj":"1531","obj":"MESH:D002318"},{"id":"A1532","pred":"tao:has_database_id","subj":"1532","obj":"MESH:C000657245"},{"id":"A1533","pred":"tao:has_database_id","subj":"1533","obj":"MESH:C000657245"},{"id":"A1534","pred":"tao:has_database_id","subj":"1534","obj":"MESH:C000657245"},{"id":"A1535","pred":"tao:has_database_id","subj":"1535","obj":"MESH:D007239"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Currently, there are multiple in vitro experiments and preclinical studies being performed around the world to test novel COVID-19 therapies, which are quickly moving into clinical trials. Importantly, the early efficacy results have been limited to small-scale clinical studies in which the safety profiles have not been well-identified. The safety profiles will be critical for COVID-19 patients with underlying comorbidities such as cardiovascular dysfunction. Therefore, as there is a need for rapid clinical translation and a wide use of novel therapies for COVID-19, continued attention to safety profiles is important. The rapid spread of COVID-19 globally continues to impact susceptible populations, like elderly patients and individuals with underlying comorbidities. While underlying cardiovascular issues are impacted by COVID-19 infection, many existing and novel therapeutic strategies have direct adverse cardiovascular effects, highlighting the importance for consideration in new drug research and development."}